Policy Statement

1. Measurement of antidrug antibodies in an individual receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum tumor necrosis factor (TNF) blocking agent levels, is considered investigational.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

There are many types of monoclonal antibodies (a type of immunotherapy) used to treat a variety of conditions (autoimmune diseases, cancer, etc.). In addition to testing for blood levels of the therapeutic agent, it is also possible to measure antibodies to the therapeutic MA (Anti-Drug Antibodies or ADA) that can limit its effectiveness. However, the ADA testing has not been shown to be consistently helpful in clinical management (adjusting dosage, changing to another agent, etc.) that results in improved patient outcomes. Some monoclonal antibodies (mainly used for anti-inflammatory treatment) include Tumor Necrosis Factor (TNF) blockers (infliximab, adalimumab), integrin blockers (vedolizumab), and interleukin blockers (ustekinumab).

Selected U.S. Food and Drug Administration (FDA)-approved biologic agents that may involve testing of therapeutic levels or antibody levels to them include but are not limited to:
- Infliximab (e.g., Remicade, Inflectra, Renflexis)
- Adalimumab (e.g., Humira; Amjevita, Abrilada)
- Vedolizumab (e.g., Entyvio)
- Ustekinumab (e.g. Stelara)

Coding
The following specific CPT codes may be used:
- **80145**: Adalimumab
- **80230**: Infliximab
- **80280**: Vedolizumab

According to materials from Prometheus Laboratories on Anser™ IFX, Anser™ ADA and Anser VDX, these tests will be reported using 1 unit of the following CPT code:
- **84999**: Unlisted chemistry procedure

Description

Biologic agents used to treat autoimmune diseases include infliximab, adalimumab, vedolizumab, and ustekinumab. Infliximab (Remicade) is an intravenous tumor necrosis factor α blocking agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, Crohn disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and ulcerative colitis. Adalimumab (Humira) is a subcutaneous tumor necrosis factor α inhibitor that is FDA approved for the treatment of Crohn disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriatic arthritis in adults and those with juvenile idiopathic arthritis, hidradenitis suppurativa, and uveitis. Vedolizumab (Entyvio) is an intravenous integrin receptor antagonist that is FDA approved for treatment of ulcerative colitis and Crohn Disease in adults. Ustekinumab (Stelara) is an intravenous
and subcutaneous human interleukin-12 and -23 antagonist that is FDA approved for the treatment of psoriatic psoriasis, Crohn disease, and ulcerative colitis in adults, and plaque psoriasis in children and adults. Following the primary response to these medications, some patients become secondary nonresponders. The development of antidrug antibodies is considered a cause of this secondary nonresponse.

**Related Policies**

- N/A

**Benefit Application**

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Prometheus Laboratories, a College of American Pathologists-accredited lab under the Clinical Laboratory Improvement Amendments, offers 4 non-radio-labeled, fluid-phase homogenous mobility shift assay tests: called Anser IFX (for infliximab), Anser ADA (for adalimumab), Anser VDZ (for vedolizumab), and Anser UST (for ustekinumab). The tests measure both serum drug concentrations and ADA. They are not based on an ELISA test, and can measure ADA in the presence of detectable drug levels, improving on a major limitation of the ELISA method.

**Rationale**

**Background**

*Infliximab, Adalimumab, Vedolizumab, and Ustekinumab in Autoimmune Diseases*

Biologic agents (e.g., infliximab, adalimumab, vedolizumab, or ustekinumab) are used to treat multiple inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (e.g., Crohn disease, ulcerative colitis), ankylosing spondylitis, and plaque psoriasis. These agents are generally given to patients who fail conventional medical therapy, and they are typically highly effective for the induction and maintenance of clinical remission. However, not all patients respond, and a high proportion of patients lose response over time. It is estimated that 1 in 3 patients do not respond to induction therapy (primary nonresponse); further, among initial responders, response wanes over time in approximately 20% to 60% of patients (secondary nonresponse). The reasons for therapeutic failures remain a matter of debate but include accelerated drug clearance (pharmacokinetics) and neutralizing agent activity.
Measurement of Serum Antibodies to Selected Biologic Agents

Detection of Antidrug Antibodies
The detection and quantitative measurement of ADA is difficult, owing to drug interference and identifying when antibodies likely have a neutralizing effect. First-generation assays (i.e., enzyme-linked immunosorbent assays [ELISA]) can measure only ADA in the absence of detectable drug levels, due to the interference of the drug with the assay. Other techniques available for measuring antibodies include the radioimmunoassay method and, more recently, the homogenous mobility shift assay using high-performance liquid chromatography. Disadvantages of the radioimmunoassay method are associated with the complexity of the test and prolonged incubation time, along with safety concerns related to the handling of radioactive material. The homogenous mobility shift assay measures ADA when infliximab is present in serum. Studies evaluating the validation of results among different assays are lacking, making interstudy comparisons difficult. One retrospective study by Kopylov et al (2012), which evaluated 63 patients, demonstrated comparable diagnostic accuracy between 2 different ELISA methods in patients with inflammatory bowel disease (i.e., double-antigen ELISA and antihuman lambda chain-based ELISA). This study did not include an objective clinical and endoscopic scoring system for validation of results.

Treatment Options for Secondary Nonresponse to Biologic Agents
A diminished or suboptimal response to infliximab, adalimumab, vedolizumab, or ustekinumab can be managed in several ways: shortening the interval between doses, increasing the dose, switching to a different biologic agent (in patients who continue to have a loss of response after receiving the increased dose), or switching to a non-biologic agent.

Literature Review
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Antibodies to Infliximab, Adalimumab, Vedolizumab, and Ustekinumab

Clinical Context and Test Purpose
The purpose of testing serum antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab in patients with arthritis (e.g., rheumatoid, psoriatic, or juvenile idiopathic), inflammatory bowel disease (IBD), ankylosing spondylitis, or plaque psoriasis is to improve health outcomes.

The question addressed in this evidence review is: Does testing for serum antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab improve the net health outcome in patients with arthritis (e.g., rheumatoid, psoriatic, or juvenile idiopathic), IBD, ankylosing spondylitis, or psoriasis? The following PICO was used to select literature to inform this review.

Populations
The relevant populations of interest are individuals with arthritis (e.g., rheumatoid, psoriatic, or juvenile idiopathic), IBD, ankylosing spondylitis, or plaque psoriasis. Both pediatric and adult patients were considered in this review.
Interventions
The test being considered is testing for serum antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab.

Comparators
The following practice is currently being used to manage arthritis, IBD, ankylosing spondylitis, or plaque psoriasis: standard of care.

Outcomes
The general outcomes of interest are test validity, change in disease status, health status measures, quality of life, and treatment-related morbidity.

Follow-up over months to years is of interest to the relevant outcomes.

Study Selection Criteria
For the evaluation of the clinical validity of this test, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
There is a substantial body of evidence (numerous systematic reviews and meta-analyses) examining associations between antidrug antibodies (ADA) and nonresponse as well as an injection- or infusion-site reactions. Accordingly, this review of the evidence on clinical validity focuses on the most current systematic reviews (see Tables 1 through 3) and studies published after the search dates of those reviews, as well as relevant studies not included in identified reviews (e.g., those focusing on adverse reactions and ADA). In addition, pediatric studies were included in the review, although the majority of data is in the adult population.

Systematic Reviews
Six reviews published from 2012 through 2017 were identified. The number of studies included ranged from 117 to 68, varying by review objectives and conditions of interest. Although not delineated here, there was considerable overlap in selected studies across reviews.

The systematic review and meta-analysis by Pecoraro et al (2017) selected 34 studies (N=4273 patients), including randomized controlled trials (RCTs; n=4), prospective observational (n=22), retrospective observational (n=6), and cross-sectional (n=2). Studies evaluated rheumatoid arthritis (RA; n=18), ulcerative colitis (n=2), Crohn disease (CD; n=5), psoriatic arthritis (n=4), ankylosing spondylitis (n=5), plaque psoriasis (n=4), and spondyloarthritis (SpA; n=1). Most patients (45%) received infliximab, 35% received adalimumab, and 21% received etanercept. None received golimumab or certolizumab. Reviewers identified studies published through August 2016 and rated study quality as good (n=17), fair (n=16), or poor (n=1). The effect of ADA was evaluated in 19 studies, showing a significant (p<.05) reduction of response (relative risk [RR]=0.43; 95% confidence interval [CI], 0.3 to 0.63) in ADA-positive patients relative to ADA-negative patients, with adalimumab therapy demonstrating a greater reduction (RR=0.40; 95% CI, 0.25 to 0.65; p<.001) than infliximab (RR=0.37; 95% CI, 0.2 to 0.7; p<.001). Measures of heterogeneity were 84%, 57%, and 79%, respectively. Fourteen studies reported on the effect of ADA on clinical response (see Table 4). Eleven studies found the risk of developing ADA to be significantly (p=.03) lower in patients treated with
concomitant methotrexate therapy relative to those treated without methotrexate (RR=0.65; 95% CI, 0.47 to 0.9). Studies comparing treatment response with nonresponse (n=15) found responders to have a significantly (p<0.001) lower risk of developing ADA relative to nonresponders (RR=0.31; 95% CI, 0.18 to 0.52). The presence of ADA was associated with a significant reduction of tumor necrosis factor (TNF-\(\alpha\)) serum concentration (see Table 5). Of the 20 studies (n>2800 patients) reporting data on adverse events, 31% (n=2 studies) developed infections, 18% (n=12 studies) developed injection-site reactions, 8% (n=11 studies) discontinued treatment due to adverse events, and 5% (n=1 study) developed serious adverse events. Although ADA significantly reduced TNF-\(\alpha\) response, the results should be viewed cautiously due to reported study limitations, including small numbers of studies assessed and considerable heterogeneity.

The systematic review and meta-analysis by Thomas et al (2015) included 68 studies (N=14651 patients). Patients had RA (n=8766), SpA (n=1534), or IBD (n=4351). Immunogenicity was examined for infliximab (39 comparisons), adalimumab (15), etanercept (5), golimumab (14), and certolizumab (8). Reviewers identified studies published through December 2013 and included 38 RCTs and 30 observational studies (study quality rated as good [n=32], moderate [n=26], poor [n=10]). The pooled prevalence of ADA varied by disease and drug (see Table 1, highest with infliximab: 25.3%). Duration of exposure (reported in 60 studies) was examined for its potential effect on the development of ADA, and most studies employed enzyme-linked immunosorbent assays (ELISA). The presence of ADA was associated with lower odds of response across most drugs and diseases (see Table 2). An exception was in studies of IBD. Use of immunosuppressive agents substantially decreased the risk of ADA (odds ratio [OR], 0.26; 95% CI, 0.21 to 0.32). Finally, infusion reactions and injection-site reactions were more common (see Table 3) when ADA were detectable (OR=3.25). Evaluation of potential publication bias and overall assessment (e.g., GRADE or similar) for the body of evidence were not reported. Additionally, no measures of heterogeneity were reported.

The systematic review by Meroni et al (2015) searched PubMed through March 2013 and included 57 studies of infliximab (n=34), adalimumab (n=18), and etanercept (n=5). Studies primarily included patients with IBD and RA, but also SpA and psoriasis. Most had prospective cohort designs (n=42), and a formal assessment of study quality (bias) was not reported. Reviewers noted considerable variability in the time from drug administration to ADA and drug bioavailability testing across studies. Various antibody testing assay methods were used and included solid-phases radioimmunoassay (RIA), traditional ELISA, fluid-phase RIA, and bridging ELISA; cutoffs for positive test results were also inconsistently reported. The ranges of patients with detectable ADA varied substantially (see Table 1) but were consistent with other reviews. Qualitatively, the presence of antibodies to infliximab (ATI) was associated with lower levels of infliximab and lower risk of disease control or remission. The presence of antidrug antibody also increased the risk of infusion reactions. When ascertained, the time to development of antidrug antibody varied from as little as 16 weeks to over a year. The time to antibodies to adalimumab (ATA) positivity varied (e.g., 50% of patients with detectable ATA at 28 weeks to a median time of 1 year). Finally, for both infliximab and adalimumab, immunosuppression was associated with less ADA positivity. Reviewers concluded that “…the lack of homogeneity in study design and methodologies used … limited the opportunity to establish the time-course and clinical consequences of anti-drug antibody development…” Although qualitative, reviewers included many studies and provided a detailed review of each not reported by the other meta-analyses.

Nanda et al (2013) conducted a meta-analysis of studies that reported on clinical outcomes according to the presence or absence of ADA in patients with IBD. Several databases were searched to February 2012 (1 was searched to August 2012). Eleven studies involving 707 patients were selected. Six studies (2 RCTs, 1 prospective cohort study, 3 retrospective cohort studies) were included. Selected studies failed at least 1 quality domain (study eligibility criteria, measurement of exposure and outcome, control for confounders, completeness of follow-up), and all studies had a high-risk of bias. The prevalence of detectable ADA in the included studies ranged from 22.4% to 46% (see Table 1). The outcome of interest was a loss of response to infliximab, defined as “relapse of clinical symptoms in
patients who were in clinical remission from, or had responded to, infliximab. Measures of loss of response varied across studies and included clinician assessment, standardized scales (Crohn’s Disease Activity Index [CDAI], Harvey-Bradshaw Index, Simple Clinical Colitis Activity Index), and the requirement for surgery or presence of a nonhealing fistula. Patients with ATIs had a 3-fold greater risk of loss of response than those without ADAs (RR=3.2; 95% CI, 2.0 to 5.0; shown in Table 2 as the RR of clinical response in treated vs untreated patients to allow comparison with other meta-analyses). This result was influenced primarily by 532 patients with CD (RR=3.2; 95% CI, 1.9 to 5.5); pooled results for 86 patients with ulcerative colitis were not statistically significant (pooled RR=2.2; 95% CI, 0.5 to 9.0). Eighty-nine patients with unspecified IBD also were included in the meta-analysis. In addition to potential bias in included studies and heterogeneity in outcome assessment, the meta-analysis was limited by variability in the method of ADA detection (double-antigen ELISA, anti-human lambda chain-based ELISA, fluid-phase RIA).

Garces et al (2013) performed a meta-analysis of studies of infliximab and adalimumab used to treat RA, IBD, SpA, and psoriasis. Databases were searched to August 2012, and reviewers selected 12 prospective cohort studies involving 860 patients (540 with RA, 132 with SpA, 130 with IBD, 58 with psoriasis). The outcome of interest was a response, assessed using standard assessment scales for rheumatologic diseases (e.g., European League Against Rheumatism criteria for RA; Assessment in Ankylosing Spondylitis 20% response criteria, or Ankylosing Spondylitis Disease Activity Score for spondyloarthritis; Psoriasis Area and Severity Index for psoriasis) and clinician assessment for IBD. Overall, detectable ADA were associated with a 68% reduction in drug response (pooled RR=0.32). Significant heterogeneity was introduced by varying use of immunosuppressant therapy (e.g., methotrexate) across studies. To assess ADA, most studies used RIA, which is less susceptible than ELISA to drug interference and may be more accurate.

Lee et al (2012) conducted a meta-analysis of patients with IBD receiving infliximab to estimate the prevalence of ADA, the effect of ADA on the prevalence of infusion reactions, and the effect of ADA on disease remission rates. Databases were searched through October 2011, and 18 studies (N=3326 patients) were selected. Studies included RCTs, 5 prospective cohort studies, and 4 retrospective cohort studies. The prevalence of ADA was 45.8% when episodic infusions of infliximab were given and 12.4% when maintenance infliximab was given (see Table 1). Patients with ADAs were less likely to be in clinical remission (see Table 2), but this finding was not statistically significant (RR=0.90; p=0.10). Rates of infusion reactions were significantly higher in patients with ADA (RR=2.07; see Table 3). Immunosuppressants resulted in a 50% reduction in the risk of developing ADAs (p<0.001). Reviewers concluded that patients with IBD who test positive for ADAs are at an increased risk of infusion reactions but have rates of remission similar to patients who test negative for ADAs.

Table 1. Estimated Prevalence of Antidrug Antibodies From Meta-Analyses

<table>
<thead>
<tr>
<th>Study</th>
<th>Included Studies</th>
<th>Drugs</th>
<th>Disease</th>
<th>Prevalence of ADA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IFX</td>
<td>ADL</td>
<td>Other*</td>
</tr>
<tr>
<td>Lee et al (2012)</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episodic</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nanda et al (2013)</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas et al (2015)</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Measurement of Serum Antibodies to Selected Biologic Agents

#### Table 2. Results From Meta-Analyses of Antidrug Antibodies and Clinical Response

<table>
<thead>
<tr>
<th>Study</th>
<th>Include Studies</th>
<th>Drugs</th>
<th>Disease</th>
<th>Clinical Response: ADA vs None</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IFX</td>
<td>ADL</td>
<td>Other&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lee et al (2012)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>18</td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
</tr>
<tr>
<td>Nanda et al (2013)&lt;sup&gt;7&lt;/sup&gt;</td>
<td>11</td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
</tr>
<tr>
<td>Garces et al (2013)&lt;sup&gt;8&lt;/sup&gt;</td>
<td>12</td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
</tr>
<tr>
<td>Thomas et al (2015)&lt;sup&gt;9&lt;/sup&gt;</td>
<td>4</td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
</tr>
</tbody>
</table>

**ADA: antidrug antibodies; ADL: adalimumab; CI: confidence interval; I: heterogeneity measure; IBD: inflammatory bowel disease; IFX: infliximab; RA: rheumatoid arthritis; SpA: spondyloarthropathy.**

<sup>a</sup> Includes etanercept, golimumab, certolizumab.

<sup>b</sup> Also psoriasis.
Table 3. Increased Risk of Adverse Reactions Associated With the Presence of Antidrug Antibodies

<table>
<thead>
<tr>
<th>Study</th>
<th>Include Studies</th>
<th>Drugs</th>
<th>Disease</th>
<th>Adverse Reactions: ADA vs None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al (2012)^6</td>
<td>18</td>
<td>IFX</td>
<td>IBD</td>
<td>2.07 (1.61 to 2.67)^a</td>
</tr>
<tr>
<td>Thomas et al (2015)^8</td>
<td>NR</td>
<td>ADL</td>
<td>RA</td>
<td>3.25 (2.35 to 4.51)</td>
</tr>
</tbody>
</table>

ADA: antidrug antibodies; ADL: adalimumab; CI: confidence interval; IBD: inflammatory bowel disease; IFX: infliximab; NR: not reported; OR: odds ratio; RA: rheumatoid arthritis; RR: relative risk; SpA: spondyloarthritis.
^a Infusion reaction.

Table 4. Effect of Antidrug Antibodies on Clinical Response

<table>
<thead>
<tr>
<th>Outcome Measures</th>
<th>No. of Studies</th>
<th>MD</th>
<th>95% Confidence Interval</th>
<th>I², %</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease Activity Score 28</td>
<td>9</td>
<td>0.93</td>
<td>0.41 to 1.44</td>
<td>84</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>BASDAI</td>
<td>2</td>
<td>-0.62</td>
<td>-1.51 to 0.27</td>
<td>0</td>
<td>.17</td>
</tr>
<tr>
<td>ASDAS</td>
<td>2</td>
<td>0.96</td>
<td>-0.27 to 2.2</td>
<td>0</td>
<td>.13</td>
</tr>
<tr>
<td>Psoriasis Area Severity Index</td>
<td>1</td>
<td>4.7</td>
<td>-1.15 to 9.25</td>
<td>NR</td>
<td>.04</td>
</tr>
</tbody>
</table>

ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; I²: heterogeneity measure; MD: mean difference; NR: not reported.

Table 5. Evaluation of Antidrug Antibody Concentration

<table>
<thead>
<tr>
<th>Outcome Measures</th>
<th>No. of Studies</th>
<th>MD, mg/L</th>
<th>95% Confidence Interval</th>
<th>I², %</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA-positive vs ADA-negative</td>
<td>8</td>
<td>-7.07</td>
<td>-8.9 to -5.25</td>
<td>98</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Responders vs no responders</td>
<td>13</td>
<td>2.77</td>
<td>1.97 to 3.58</td>
<td>82</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Adalimumab therapy</td>
<td>6</td>
<td>5.07</td>
<td>3.77 to 6.36</td>
<td>62</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Infliximab</td>
<td>4</td>
<td>2.74</td>
<td>0.59 to 4.89</td>
<td>62</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Etanercept</td>
<td>3</td>
<td>0.85</td>
<td>0.41 to 1.13</td>
<td>82</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>DAS28 change from baseline</td>
<td>8</td>
<td>-2.18</td>
<td>-2.91 to -1.44</td>
<td>97</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

ADA: antidrug antibodies; DAS28: Disease Activity Score in 28 joints; I²: heterogeneity measure; MD: mean difference; TNF: tumor necrosis factor.

Cohort Studies
BCBSA identified several publications not included in a systematic review. The results of the most recent publications are consistent with the conclusions of the systematic reviews.

Cludts et al (2017) conducted a single-center retrospective cohort analysis of patients with RA (n=18), psoriatic arthritis (n=9), or ankylosing spondylitis (n=12) in Italy.^10 Serum samples were taken prior to adalimumab therapy and after 12 and 24 weeks of treatment. Psoriatic arthritis and ankylosing spondylitis patients were grouped together (SpA) due to axial involvement in all psoriatic arthritis patients. Although adalimumab levels varied among patients (0 to 30 mg/mL), median levels were significantly lower at 12 and 24 weeks in ATA-positive samples, and antibody formation was associated with decreasing levels of circulating adalimumab. A reporter gene assay detected neutralizing antibodies against TNF antagonists in ATA-positive, therapeutic-negative patients; however, neutralization could not be confirmed in all ATA-positive samples due to adalimumab interference. There was a negative correlation between ATA levels and adalimumab in all groups, with 43.6% and 41% of the adalimumab-treated patients developing antibodies at 12 and 24 weeks, respectively. These percentages increased to 48.7% and 46% after subjecting the samples to acid treatment. There was a negative correlation between adalimumab trough levels and Disease Activity Score in 28 joints (DAS28) and Bath Ankylosing Spondylitis Disease Activity Index scores (p<.001). There were no significant differences in Bath Ankylosing Spondylitis Disease Activity Index scores.
between ATA-positive and ATA-negative patients at 12 or 24 weeks. Study findings are consistent with others, suggesting that adalimumab levels can serve as an indicator of ATA; however, limitations included small sample size, retrospective research design, and failure to confirm neutralization in all ATA-positive samples.

Using an observational, cross-sectional study design, Ara-Martin et al (2017) analyzed the impact of immunogenicity on response to anti-TNF therapy in 137 adults with moderate-to-severe plaque psoriasis at 35 centers in Spain between 2012 and 2014. All patients experienced secondary nonresponse to adalimumab (n=65), etanercept (n=47), and infliximab (n=19) after 6 or more months of treatment. Serum ADA was identified in 48%, 0%, and 42% of patients treated with adalimumab, etanercept, and infliximab, respectively. Loss of efficacy was assessed using the Psoriasis Area and Severity Index (PASI; >5), 75% improvement in PASI score from baseline (PASI75), and/or the Physician Global Assessment (>2). Physician Global Assessment values for ADA-positive versus ADA-negative patients were significantly worse in the adalimumab group (3.7 vs 3.2; p=0.02) but not in the infliximab group. There was a significant negative linear correlation between serum drug concentrations and ADA in the adalimumab group (p=0.001) and among the 3 groups combined (p=0.001), and a significant (p=0.019) correlation between serum ADA titer and body surface area. Unlike the other studies, in this study, the use of concomitant antirheumatic drugs was not associated with anti-TNF immunogenicity in any of the groups. This study provided evidence of antibody development against adalimumab and infliximab (not against etanercept) in patients with psoriasis, with ADA formation accounting for half of the secondary nonresponse associated with these therapies. However, conclusions were limited due to the cross-sectional study design, the use of ELISA to detect ADAs due to drug interference, the potential presence of neutralizing antibodies as confounding factors, and limited information about patients’ health status prior to the study period.

A case-control, longitudinal study by Lombardi et al (2016) evaluated possible confounding factors by analyzing adalimumab treatment for psoriasis in 5 distinct groups, including individuals who received: biologic therapies after switching from adalimumab (n=20); ongoing adalimumab therapy (n=30); novel adalimumab therapy (n=30); biologic therapies other than adalimumab (n=15); and no treatment with immunosuppressants or biologics (n=15), serving as a quasi-control. At a 12-month follow-up, ADA was highest (87%) in patients who received biologic therapies after switching from adalimumab. The false-positive rate was 23% for adalimumab detection and 22% for anti-adalimumab antibodies in individuals who were never treated with adalimumab. There were no significant differences in median PASI scores between the anti-adalimumab antibody-negative patients (1.1) and the anti-adalimumab antibody-positive patients (4.0). There was no association between PASI score or TNF-α concentration and the presence of anti-adalimumab antibodies in patients receiving adalimumab. Additionally, there were no significant differences in TNF-α and C-reactive protein concentrations. Study limitations included the observational design, small sample size, use of ELISA to measure ADA, and high variability of results. The authors concluded that the assay has limited clinical utility.

Arstikyte et al (2015) prospectively evaluated the association between ADA and adverse events, clinical response, and serum drug levels in 143 symptomatic patients (62 with RA, 81 with SpA; mean age, 45 years) treated with TNF blockers in Lithuania. All patients receiving adalimumab or infliximab were tested and 1 in 3 patients was given etanercept (because it is more commonly used). A response in RA patients was defined as either good, moderate, or low using European League Against Rheumatism criteria; SpA disease activity was considered inactive, moderate, high, or very high by established criteria, with inactive and moderately active disease defined as a response. At least 3 months after therapy initiation, a single serum sample was obtained prior to dosing between 2012 and 2013; disease activity and other patient characteristics (e.g., symptom duration, health status) were assessed concurrently. Serum adalimumab, infliximab, and etanercept levels were obtained; ADA was assayed using a bridging ELISA. Of 57 patients receiving infliximab, 14 (24.6%) had detectable antibodies, with 13 of the 14 undetectable infliximab trough levels. Disease activity at baseline was unassociated with the development of ADA in either disease. In patients achieving a
response, infliximab and adalimumab trough levels were higher, but not significantly (p=.09 and p=.14, respectively). However, adalimumab concentrations were significantly higher in nonresponders (p<.001). ATI were associated with infusion reactions but with little certainty (OR=5.9; 95% CI, 1.0 to 33.3) as was stopping infliximab treatment or changing agent. Study strengths included its prospective design, standardized assessments, and responder definition. Limitations were the small number of nonresponders and lack of specificity on whether any eligible participants declined enrollment.

Jani et al (2015) measured ADA and RIA together, with drug levels in 331 RA patients treated with adalimumab (n=160) or etanercept (n=171) between 2008 and 2013. Patients were participants in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, conducted in 60 centers across the United Kingdom. Disease activity was assessed using the DAS28. The response was evaluated using European League Against Rheumatism response criteria or change in the DAS28 score. Following 12 months of adalimumab therapy, ADA were detectable in 24.8% of patients (almost all were detectable by 6 months) and were associated with lower serum drug levels. Both routine (nontrough) drug levels and ATA were associated with DAS28 scores at 12 months. In predicting European League Against Rheumatism nonresponse, the area under the curve for an adalimumab concentration less than 5 mg/mL at 3 months was 0.66 (95% CI, 0.55 to 0.77) and 0.68 (95% CI, 0.54 to 0.81) for the presence of ADA. None of the etanercept patients developed detectable ADA. Although derived from a well-established observational study designed to examine predictors (genetic and other) of treatment response, ADA serum levels were not used to inform treatment decisions. Study results corroborated other research findings.

Frederiksen et al (2014) conducted a single-center retrospective cohort study of IBD patients treated with infliximab (n=187) or adalimumab (n=57) in Denmark. ADA were assayed using fluid-phase RIA; 49% of infliximab-treated patients developed antibodies compared with 21% of those treated with adalimumab. Development of ATA was associated with secondary nonresponse: the positive predictive value was 91% (95% CI, 59% to 100%), sensitivity was 50% (95% CI, 27% to 73%); the negative predictive value was 74% (95% CI, 57% to 87%), and specificity was 97% (95% CI, 82% to 100%) (values varied by adalimumab trough levels). The authors also reported that patients switching from infliximab to adalimumab who had antibodies were more likely to develop ATA. These findings are consistent with other studies and evaluations of ADA using RIA (a strength of this study). Conclusions were limited by the retrospective design and sample size.

While many studies have evaluated the clinical validity using single ADA measurements, at least 1 assessed their persistence over time. Vande Casteele et al (2013) analyzed infliximab trough and ATI levels using a homogeneous mobility shift assay with banked serum obtained from 90 IBD patients treated between 1999 and 2011. ATI levels had been previously assayed using an ELISA-based test. A total of 1232 samples were evaluated (mean, 14 per patient). Treatment decisions were made solely on clinical evaluation and C-reactive protein levels. ATI were detected in 53 (59%) of 90 patients but subsequently were nondetectable in 15 (28%) of the 53. Persistent ATIs were associated with discontinuation of infliximab (RR=5.1; 95% CI, 1.4 to 19.0), but the wide CI reflects considerable uncertainty. Although the transience of ATI in IBD has not been carefully scrutinized, if replicated, these results would suggest interpreting a single ATI result cautiously.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.
Several algorithms have been developed to manage patients with IBD\(^{19,20,21}\) and RA\(^{22}\), who have relapsed during TNF-inhibitor therapy. These algorithms are generally based on evidence that has indicated an association between ADA, reduced serum drug levels, and relapse. None of the algorithms have included evidence demonstrating improved health outcomes, such as reduced time to recovery from relapse (response).

Syversen et al (2021) reported on results of a randomized, parallel-group, open-label trial of 411 adults with RA, spondyloarthritis, psoriatic arthritis, ulcerative colitis, CD, or psoriasis who received either proactive therapeutic drug monitoring of infliximab therapy based on serum infliximab level and ADA, or standard therapy without serum infliximab level or ADA.\(^{23}\) Serum trough infliximab levels and ADA were measured at each infusion in the therapeutic drug monitoring group. The infliximab dose or interval could be adjusted based on the therapeutic range during induction and during treatment. If ADA was greater than 50 mcg/L at any point, therapy with infliximab was switched to a different agent.

There was no difference between the therapeutic drug monitoring group and standard therapy group in clinical remission at week 30 (50.5% vs 53% of patients, respectively; \(p=.78\)).\(^{23}\) During infliximab treatment, 36 (18%) patients in the therapeutic drug monitoring group and 34 (17%) in the standard therapy group developed ADAs \(\geq 15\) mcg/L. Antidrug antibodies \(\geq 50\) mcg/L (the threshold for discontinuation) occurred in 20 (10%) patients in the therapeutic drug monitoring group and 30 (15%) in the standard therapy group. The remission rate in patients who developed ADAs was 56% in the therapeutic drug monitoring group and 35% in the standard therapy groups. The trial was limited by the small sample size of subjects who developed ADAs.

Steenholdt et al (2014) reported on results of a noninferiority trial and cost-effectiveness analysis of 69 patients with CD who relapsed (CDAI \(\geq 220\) and/or \(\geq 1\) draining perianal fistula) during infliximab therapy.\(^{24}\) Patients were randomized to infliximab dose intensification (5 mg/kg every 4 weeks) or algorithmic treatment based on serum infliximab level and ATI. Patients with subtherapeutic infliximab level (<0.5 μg/mL)\(^{25}\) had the infliximab dose increased if ATI were undetectable or were switched to adalimumab if ATI were detectable; patients with therapeutic infliximab level underwent repeat testing of infliximab and ATI levels if ATI were detectable or diagnostic reassessment if ATI were undetectable. Serum infliximab and ATI levels were measured in all patients using RIA in single-blind fashion (patients were unaware, but investigators were aware of test results). Randomized groups were similar at baseline; overall, 55 (80%) of 69 patients had nonfistulizing disease. Most patients (70%) had therapeutic serum infliximab levels without detectable ATI; revised diagnoses in 6 (24%) of 25 such patients in the algorithm arm\(^{26}\) included bile acid malabsorption, strictures, and irritable bowel syndrome. In both intention-to-treat and per-protocol analyses, similar proportions of patients in each randomized group achieved clinical response at week 12, defined as a minimum 70-point reduction from baseline CDAI score for patients with nonfistulizing disease and a minimum 50% reduction in active fistulas for patients with fistulizing disease (intention-to-treat, 58% in the algorithm group vs 53% in the control group; \(p=.810\); per-protocol, 47% in the algorithm group vs 53% in the control group; \(p=.781\)). Only the intention-to-treat analysis fell within the prespecified noninferiority margin of -25% for the difference between groups.

Conclusions on the noninferiority of an algorithmic approach compared with dose intensification from this trial are limited. The noninferiority margin was arguably large and was exceeded in the conservative per-protocol analysis. Dropouts were frequent and the differential between groups; 17 (51%) of 33 patients in the algorithm group and 28 (78%) of 36 patients in the control group completed the 12-week trial. A large proportion of patients (24%) in the algorithmic arm were potentially misdiagnosed (ie, CD flare was subsequently determined not to be the cause of relapse); the comparable proportion in the control arm was not reported. In most patients (80% who had nonfistulizing disease), only a subjective measure of treatment response was used (minimum 70-point reduction from baseline CDAI).
Roblin et al (2014) conducted a single-center, prospective observational study of 82 patients with IBD (n=45 CD, n=27 ulcerative colitis) with clinical relapse (CDAI score >220 or Mayo Clinic score >5) during treatment with adalimumab 40 mg every 2 weeks. For all patients, trough adalimumab levels and ADA were measured in a blinded fashion using ELISA, and adalimumab doses were optimized to 40 mg weekly. Those who did not achieve clinical remission (CDAI score <150 or Mayo score <2) within 4 months underwent repeat trough adalimumab and anti-adalimumab antibody testing and were switched to infliximab. Clinical and endoscopic responses after adalimumab optimization and after infliximab therapy for 6 months were compared across 3 groups: (1) those with a therapeutic adalimumab level (>4.9 μg/mL), (2) those with a subtherapeutic adalimumab level and undetectable ATA; and (3) those with a subtherapeutic adalimumab level and detectable ATA. After adalimumab optimization, more group 2 patients achieved clinical remission (16 [67%] of 24 patients) than group 1 (12 [29%] of 41 patients; p<.01 vs group 2) and group 3 (2 [12%] of 17 patients; p<.01 vs group 2) patients. Duration of remission was longest in group 2 (mean, 15 months) compared with group 1 (mean, 5 months) and group 3 (mean, 4 months; p<.01 for both comparisons vs group 2). At 1 year, 13 (52%) of 24 patients in group 2 maintained clinical remission compared with no patients in groups 1 or 3 (p<.01 for both comparisons vs group 2). Results were similar when remission was defined using calprotectin levels (<250 μg/g stool) or endoscopic Mayo score (<2).

Fifty-two patients (n=30 CD, n=22 ulcerative colitis) who failed to achieve clinical remission after adalimumab optimization were switched to infliximab. More patients in group 3 achieved clinical remission (12 [80%] of 15 patients) than in group 1 (2 [7%] of 29 patients) or group 2 (2 [25%] of 8 patients; p<.01 for both comparisons vs group 3). Duration of response after switching to infliximab was longest in group 3 (mean, 14 months) compared with group 1 (mean, 3 months) and group 2 (mean, 5 months; p<.01 for both comparison vs group 3). At 1 year, 8 (55%) of 15 patients in group 3 maintained clinical remission compared with no patients in groups 1 or 2 (p<.01 for both comparisons vs group 3). Results were similar using objective measures of clinical remission (calprotectin level, endoscopic Mayo score).

These results suggested that patients with IBD who relapse on adalimumab and have subtherapeutic serum adalimumab levels may benefit from a higher adalimumab dose if ATA is undetectable or from a change to another TNF inhibitor if ATA is detectable. Relapsed patients who have therapeutic serum adalimumab levels may benefit from change to a different drug class. The strengths of the study included its use of subjective and objective measures of remission and blinded serum drug level and ATA monitoring. However, results were influenced by the small sample size, use of ELISA for antibody testing, and lack of ADA levels for decision making. A subsequent study comparing the management using the algorithm proposed with usual care is needed. Finally, the lead author of the study received lecture fees from the ADA test provider (Theradiag).

Afif et al (2010) evaluated the clinical utility of measuring ATI (referred to as human antichimeric antibodies in the study) and infliximab concentrations by retrospectively reviewing patient medical records. Record review from 2003 to 2008 identified 155 patients who had had ATI, had data on infliximab concentrations and met the study inclusion criteria. A single physician ordered 72% of the initial tests. The authors retrospectively determined clinical response to infliximab. Forty-seven percent of patients were on concurrent immunosuppressive medication. The main indications for testing were a loss of response to infliximab (49%), partial response after initiation of infliximab (22%), and possible autoimmune or delayed hypersensitivity reaction (10%). ATI were identified in 35 (23%) patients and therapeutic infliximab concentrations in 51 (33%) patients. Of 177 tests assessed, the results impacted treatment decisions in 73%. In ATI-positive patients, change to another anti-TNF agent was associated with a complete or partial response in 92% of patients, whereas dose escalation occurred in 17%.

The authors concluded that the measurement of ATI and infliximab concentration had a clinically useful effect on patient management. The strategy of increasing infliximab dose in patients with ATI was ineffective whereas, in patients with subtherapeutic infliximab concentrations this strategy was...
a good alternative to changing to another anti-TNF agent.\textsuperscript{29} Study limitations included the retrospective design and use of ELISA testing for ATI. Because there was no control group, I cannot determine what changes in management would have been made absent ATI measurement. Because clinicians are likely to change management for patients who do not achieve or maintain a clinical response, it is important to understand how these management decisions differ when ATI is measured.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of testing anti-TNF-\(\alpha\) inhibitor antidrug antibody or ATA in this population has not been established, a chain of evidence supporting clinical utility cannot be constructed.

**Section Summary: Antibodies to Infliximab, Adalimumab, Vedolizumab, and Ustekinumab**
A large body of evidence has evaluated the clinical validity of ADA testing. ADA has been associated with secondary nonresponse in RA, SpA, and possibly IBD. The presence of ADA has been consistently associated with an increased risk of an infusion-site reaction related to infliximab and injection-site reactions related to adalimumab. A concomitantly administered immunosuppressant agent may reduce the risk of developing ADA. Although ADA significantly reduced TNF-\(\alpha\) response in a recent meta-analysis, considerable heterogeneity limits those findings. In addition, a recent observational study found no association between concomitant immunosuppressants and anti-TNF immunogenicity in patients with psoriasis; and a second cohort study found no association between PASI score or TNF-\(\alpha\) concentration and the presence of anti-adalimumab antibodies in patients receiving adalimumab to treat psoriasis.

Convincing evidence for the clinical utility of ADA testing is currently lacking. An RCT did not find a difference in relapse rates with therapeutic drug monitoring of infliximab using trough levels and ADA compared to standard therapy without monitoring these levels. Uncontrolled retrospective studies in IBD have demonstrated the impact of ADA testing on treatment decisions but cannot demonstrate improved patient outcomes compared with a no-testing strategy. Additional limitations of these studies included a lack of clinical follow-up after treatment decisions were made and a lack of clinical assessments to guide treatment decisions. Additionally, the determination of a clinically relevant threshold for the ADA level is complicated by the use of various assay methods. A small, nonrandomized prospective study suggested that ADA levels may be informative in relapsed patients with IBD who have low serum adalimumab levels, but this finding requires confirmation in larger, randomized trials. Methodologic flaws, including relapse misclassification, limit conclusions from the RCT in patients with relapsed IBD. Direct or indirect evidence for clinical utility in patients with RA or SpA was not identified. Finally, although ADA is associated with increased risk of infliximab infusion- and adalimumab injection-site reactions, whether testing for ADA can reduce that risk is unclear. For example, the Lichtenstein (2013) systematic review of infliximab-related infusion reactions concluded: "...there is a paucity of systematic and controlled data on the risk, prevention, and management of infusion reactions to infliximab."\textsuperscript{22}

**Summary of Evidence**
For individuals who have rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis; inflammatory bowel disease (e.g., Crohn disease, ulcerative colitis); ankylosing spondylitis; or plaque psoriasis who receive evaluation for serum antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab, the evidence includes multiple systematic reviews, randomized controlled trials, and observational studies. Relevant outcomes are test validity, change in disease status, health status measures, quality of life, and treatment-related morbidity. Antibodies to biologic agents develop in a substantial proportion of treated patients and are believed to neutralize or enhance clearance of the drugs. Considerable evidence has demonstrated an association between antidrug antibodies and secondary nonresponse as well as injection-site and infusion-site reactions. The clinical usefulness of
measuring antidrug antibodies hinges on whether test results inform management changes, thereby leading to improved outcomes, compared with management directed by symptoms, clinical assessment, and standard laboratory evaluation. Limited evidence has described management changes after measuring antidrug antibodies. A randomized controlled trial did not find a difference in relapse rates with therapeutic drug monitoring of infliximab using trough levels and antidrug antibodies compared to standard therapy without monitoring these levels. A small randomized controlled trial in patients with Crohn disease comparing antidrug antibody-informed management of relapse with standard dose escalation did not demonstrate improved outcomes with the antidrug antibody-informed approach. Additionally, many assays, some having significant limitations, have been used in studies; antidrug antibody threshold values that are informative for discriminating treatment responses have not been established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Supplemental Information**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**American College of Gastroenterology**

In 2019, the American College of Gastroenterology published a guideline on ulcerative colitis (UC). The guideline stated: "In patients with moderately to severely active UC who are responders to anti-TNF [tumor necrosis factor] therapy and now losing response, we suggest measuring serum drug levels and antibodies (if there is not a therapeutic level) to assess the reason for loss of response (conditional recommendation, very low quality of evidence)."  

In 2018, the American College of Gastroenterology published a guideline on Crohn disease (CD). Although acknowledging that a detailed review of therapeutic drug monitoring was beyond the scope of the guideline, it stated: "If active CD is documented, then assessment of biologic drug levels and antidrug antibodies (therapeutic drug monitoring) should be considered."

**American Gastroenterology Association Institute**

In 2017, the American Gastroenterology Association Institute published guidelines on therapeutic drug monitoring in inflammatory bowel disease (IBD). The guidelines note that: "In the presence of sufficient trough concentrations, results of antibody testing should not guide treatment decisions. If the trough concentration is low (below the suggested threshold, in patients with active IBD) and no anti-drug antibodies are present, then the index drug should be optimized using any of the following techniques: shortening the dosing interval and/or increasing the drug dose, and/or adding an immunomodulator agent. If there is no detectable drug (zero trough concentration) and high-titer anti-drug antibodies are present, then the patient should consider switching to a different drug within the class or to a different drug class. If there is no detectable drug and low-titer antibodies are present, then one can consider trying to optimize the index drug by shortening the dosing interval and/or increasing the drug dose, and/or adding an immunomodulator agent. Typically, optimizing the drug will be attempted before changing to a different drug within the class or switching to a new drug class, although some might opt to change to a different drug within the class or switch to a new drug class. It should be noted that the reporting of anti-drug antibodies is variable between commercial assays, with some assays being very sensitive for detecting very-low-titer antibodies of limited clinical significance. Uniform thresholds for clinically relevant antibody titers are lacking. At this time, it is unclear how antibodies affect drug efficacy when both active drug
and antibodies are detected. In cases of low trough concentrations and low or high anti-drug antibodies, the evidence to clarify optimal management is lacking."

The guidelines did not address therapeutic drug monitoring in patients treated with vedolizumab or ustekinumab.

National Institute for Health and Care Excellence
In 2016, the National Institute for Health and Care Excellence issued guidance on therapeutic monitoring of TNF-α inhibitors in the treatment of patients with CD.33 The Institute recommended that laboratories monitoring TNF-α inhibitors in patients with CD who have lost response to the treatment should “work with clinicians to collect data through a prospective study, for local audit, or for submission to an existing registry.”

In 2019, the National Institute for Health and Care Excellence issued guidance on therapeutic monitoring of TNF-α inhibitors in the treatment of patients with rheumatoid arthritis.34 The Institute stated: "Enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (drug serum levels and antidrug antibodies) show promise but there is currently insufficient evidence to recommend their routine adoption in rheumatoid arthritis.” It also recommended that “laboratories currently using ELISA tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis should do so as part of research and further data collection.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
A search of ClinicalTrials.gov in September 2022 did not identify any ongoing or unpublished trials that would likely influence this review.

References
23. Syversen SW, Goll GL, Jorgensen KK, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-

**Documentation for Clinical Review**

- No records required

**Coding**

_This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy._

_The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases._
### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/31/2015</td>
<td>BCBSA Medical Policy adoption</td>
<td></td>
</tr>
<tr>
<td>03/01/2015</td>
<td>Policy revision without position change</td>
<td></td>
</tr>
<tr>
<td>02/01/2017</td>
<td>Policy revision without position change</td>
<td></td>
</tr>
<tr>
<td>01/01/2018</td>
<td>Policy revision without position change</td>
<td></td>
</tr>
<tr>
<td>01/01/2019</td>
<td>Policy revision without position change</td>
<td></td>
</tr>
<tr>
<td>03/01/2020</td>
<td>Coding update</td>
<td></td>
</tr>
<tr>
<td>06/01/2020</td>
<td>Administrative update. Policy guidelines updated.</td>
<td></td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Annual review. Policy statement, guidelines and literature updated.</td>
<td>Policy title changed from Measurement of Serum Antibodies to Monoclonal Antibodies to current one.</td>
</tr>
<tr>
<td>02/01/2022</td>
<td>Annual review. Policy statement, guidelines and literature updated.</td>
<td></td>
</tr>
<tr>
<td>01/01/2023</td>
<td>Annual review. Policy statement and literature review updated.</td>
<td></td>
</tr>
</tbody>
</table>

### Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and
effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*
### Policy Statement

**Before**
Measurement of Serum Antibodies to Selected Biologic Agents 2.04.84

**Policy Statement:**
Measurement of antidrug antibodies in a patient receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum tumor necrosis factor (TNF) blocking agent levels, is considered investigational.

---

**After**
Measurement of Serum Antibodies to Selected Biologic Agents 2.04.84

**Policy Statement:**
1. Measurement of antidrug antibodies in an individual receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum tumor necrosis factor (TNF) blocking agent levels, is considered investigational.